Navigation Links
Stevens' Dr. A. K. Ganguly receives Topliss Award Lecture from University of Michigan
Date:3/2/2011

Dr. A. K. Ganguly, Distinguished Research Professor of Chemistry at Stevens Institute of Technology, recently gave the Topliss Award Lecture at the University of Michigan. Named in honor of pioneer pharmaceutical researcher Dr. John G. Topliss, the lectures were established to recognize outstanding lifetime achievements in medicinal chemistry by academic and industrial scientists. Dr. Ganguly's lecture, "Drug Discovery Lessons Learned," was delivered in Ann Arbor on February 17.

"This recognition is a testament to Professor Ganguly's international reputation among pharmaceutical chemists," says Dr. Philip Leopold, Director of the Department of Chemistry, Chemical Biology and Biomedical Engineering. "He contributes greatly to the high quality of research towards discovery of biologically active molecules at Stevens."

Dr. Ganguly joined Stevens in 1999, after more than thirty years of pharmaceutical industry research. He received his Ph.D. from Imperial College, London, and continued to work with his advisor, Sir Derek Barton, at the Research Institute of Medicine and Chemistry in Cambridge, Massachusetts. At Schering-Plough Research Institute, which he joined in 1968 as a Senior Scientist, Dr. Ganguly rose to the position of Senior Vice President of Chemical Research. He has served on the scientific boards of pharmaceutical companies and consulted with biotechnology companies internationally.

Many of his significant contributions are in drug discovery. He is associated with the discovery of Ezetimibe (Zetia), a cholesterol absorption inhibitor, Noxafil (Posaconazole), a potent antifungal, Boceprevir a potent antiviral agent that inhibits HCY protease and Lonafarnib (Sarasar), a highly selective farnesyl protein transferase inhibitor for the treatment of cancer. He is also recognized for his contributions towards synthesis of many other biologically active molecules and determining structures of several antibiotics which advanced to cl
'/>"/>

Contact: Christine del Rosario
cdelrosa@stevens.edu
201-216-5561
Stevens Institute of Technology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Stevens Hospital One Step Closer to Affiliation with Swedish
2. Tufts receives patent for antibody treatment against hemolytic uremic syndrome
3. Childrens Hospital of Orange County receives largest gift in hospital history
4. Boston Medical Center critical care chief receives grant for lung injury study
5. Susan Band Horwitz, Ph.D., of Einstein, receives lifetime achievement award in cancer research
6. Susan Band Horwitz, Ph.D., receives AACR Award for Lifetime Achievement in Cancer Research
7. Apica Cardiovascular receives $5.1 million investment for improved heart surgery system
8. Yosef Shiloh, Ph.D., receives the 51st Annual AACR G.H.A. Clowes Memorial Award
9. Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial
10. UIC Center for Research on Women and Gender receives Presidential Award
11. LA BioMed researcher receives Lifetime Achievement Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- People with the ... condition called peripheral artery disease (PAD), a new study suggests. ... supply blood to the limbs, most often the legs. The ... narrowing of the arteries throughout the body. People with PAD ... Researchers analyzed data from nearly 6,800 people with PAD who ...
(Date:7/11/2014)... As part of its morcellator ... has been closely monitoring the ongoing meeting of ... Obstetrics and Gynecology Devices Panel, which has been ... risks associated with the use of power morcellators ... report published by Dow Jones Business News, a ...
(Date:7/11/2014)... Rochester, NY (PRWEB) July 11, 2014 ... Surgery ’s own, Dr. William Koenig, has topped a ... his peers, he has performed over 400 successful procedures ... , Dr. Koenig is well known across the country ... His exceptional safety record has long been the foundation ...
(Date:7/11/2014)... News) -- U.S. health officials have concluded that it,s ... anthrax during a safety mishap last month. But, ... have announced a moratorium on the transfer of any ... In a report issued Friday, the CDC outlined several ... similar incident doesn,t occur again. Last month, as many ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
Breaking Medicine News(10 mins):Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... kids is almost a nightmare to their respective parents, ... Researchers identified three factors that may increase a child's ... the disease that does not respond to commonly used ... before their first birthday which is also called symptomatic ...
... Female sexual dysfunction is associated with loss of libido, ... who have attained their menopause or whose ovaries had ... serve as an effective treatment in such sexual dysfunction, ... meeting of the American Urological Association in Anaheim, California. ...
... to improve sexual function among the hypertensive men with ... is the disease process itself, probably from reduced vascular ... a study evaluated hypertensive men with erectile dysfunction and ... 7.3% before losartan therapy to 58.5 % after losartan ...
... the current New England Journal of Medicine that an experimental ... men suffering from hemophilia. This method shows signs of ... clotting protein they lack. None of the patients suffers ... ,The study was designed only to test the safety and ...
... high doses of vitamin E may help fight diabetes. ... the world with many ravaging complications, affecting millions of ... damage, kidney failure, non healing ulcers all over the ... system. ,Diabetes is caused by the deficiency of ...
... latest mantra of Pfizer. The pharmaceutical giant has announced ... hardest hit by the AIDS virus. The decision by the ... Government winning a landmark case against pharmaceutical companies. In ... Diflucan will be given free of cost to battle HIV ...
Cached Medicine News:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN) ... studies for NG2-73, the Company's lead compound,for the ... SLEEP,2007 Annual Meeting of the Associated Professional Sleep ... studies,with NG2-73 in chronic insomnia patients are currently ...
... offers five questions to help women,learn about breast cancer ... – According to a new,GfK Roper Public Affairs survey ... the majority (76,percent) of women surveyed said they know ... unaware of the important recent,progress made in treatment. Fewer ...
Cached Medicine Technology:Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3
... Accutest H. pylori WB test ... the qualitative detection of lgG ... in human whole blood. This ... an aid in the diagnosis ...
... OraQuick is an FDA approved ... whole blood test used to ... HIV-1 infection. This CLIA waived ... of antibodies to HIV-1, requires ...
... is designed to detect the IgM ... whole blood. The QuickVue+ Infectious Mononucleosis ... erythrocytes which give a greater sensitivity ... from sheep and horse erythrocytes. QuickVue+ ...
... point-of-care diagnostic test that can reliably and ... and B. The test uses a unique ... assists viral replication by promoting the release ... ZstatFlu substrate is labeled with a chromagen. ...
Medicine Products: